We talk about benefits of omega 3 a lot in this group. But the AFIB risk from high doses is real and should be taken seriously.
Link to the 2021 meta-analysis of 7 randomized trials (on 81,210 people) referred to in the post:
Paper · Circulation · 2021Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.Conclusion: In RCTs examining cardiovascular outcomes, marine ɷ-3 supplementation was associated with an increased risk of AF. The risk appeared to be greater in trials testing >1 g/d.pmc.ncbi.nlm.nih.govAn updated 2026 meta-analysis of 35 randomized trials (in 114,592 people) was just published a few weeks ago. It confirmed that the AFIB risk from higher doses is very real in people at high risk for CVD. However, there was no increased risk from higher doses in people not at high risk for CVD. And there was no increased risk in either group from low doses:
Paper · Circ Arrhythm Electrophysiol · 2026Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals.Conclusion: This meta-analysis suggests that high-dose EPA/DHA treatment is associated with an increased risk of AF in patients at high cardiovascular disease risk, whereas low-dose EPA/DHA does not appear to increase AF risk, even in high-risk populations. Further prospective studies are needed to evaluate any potential increased risk of higher doses balanced against potential benefits.ahajournals.org


